The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Leqembi (lecanemab) to treat mild cognitive impairment and early Alzheimer’s disease, following a re-examination of the clinical data. The recommendation is only for patients who have one or no copies of the apolipoprotein E4 (APOE4) gene […]

Lecanemab: Neuzugelassener Antikörper hilft bei Alzheimer

Frankfurter Allgemeine

Frankfurt

Hesse

Germany

Lecanemab: Newly approved antibody helps with Alzheimer's

The Alzheimer's drug Lecanemab is coming onto the market in Germany. According to studies, it can slow the progression of the disease.

Das Alzheimer-Medikament Lecanemab kommt in Deutschland auf den Markt. Es kann laut Studien das Fortschreiten der Krankheit bremsen.

So wirkt das neue Alzheimer-Medikament – Experten hoffnungsvoll

Berliner Morgenpost

Funke Mediengruppe

Berlin

How the new Alzheimer's drug works – experts are hopeful

There is great hope: A new drug helps against dementia. It can significantly slow down the decline of memory. What patients need to know now.

Die Hoffnung ist groß: Ein neues Medikament hilft gegen die Demenz. Es kann den Abbau des Gedächtnisses deutlich verlangsamen. Was Patienten jetzt wissen müssen.

Media Bias/Fact Check

Treatment with the antibody Lecanemab is intended to help in the early stages of the disease.

Die Behandlung mit dem Antikörper Lecanemab soll in einem frühen Stadium der Krankheit helfen.

Erste Alzheimer-Therapie in der EU vor Zulassung

Die Presse

Styria Media Group

Vienna

Austria

First Alzheimer's therapy in the EU before approval

Medscape

United States

Leqembi Okayed for Subset of Early Alzheimer’s Patients

The European regulatory authority EMA has approved an antibody preparation for the first time. This is an important step – even if the drug is controversial.

Die europäische Zulassungsbehörde EMA hat erstmals ein Antikörperpräparat zugelassen. Das ist ein wichtiger Schritt – auch wenn das Mittel umstritten ist.

Heilsbringer oder Hype: warum die EU-Zulassung des Alzheimermittels Leqembi gut ist

Neue Zürcher Zeitung

NZZ Mediengruppe

Zürich

Zürich District

Zurich

Switzerland

Savior or hype: why the EU approval of the Alzheimer's drug Leqembi is good

The disappointment was great when a new drug against Alzheimer's was rejected by the EU's Medicines Authority (EMA) this summer.
But now the EMA has reconsidered its opinion - and approves the sale of the drug lecanemab for the treatment of certain Alzheimer's patients.
For example, it will not apply to patients with a double set of the Alzheimer's risk gene Apoe4.

Besvikelsen var stor när ett nytt läkemedel mot alzheimer fick avslag av EU:s läkemedelsmyndighet (EMA) i somras.
Men nu har EMA omprövat sitt yttrande – och godkänner försäljning av läkemedlet lecanemab för behandling av vissa alzheimerpatienter.
Till exempel kommer det inte gälla för patienter med dubbel uppsättning av alzheimerriskgenen Apoe4.

Nya läkemedlet mot  alzheimer får godkänt

Expressen

Bonnier Group

Stockholm

Stockholm County

Sweden

The new drug against Alzheimer's gets approved

10:43 After the European Medicines Agency EMA rejected the drug Leqembi in July as the first treatment for Alzheimer's disease, the green light has now been given.

10:43 Nadat het Europees geneesmiddelenagentschap EMA in juli het middel Leqembi afgekeurd had als de eerste behandeling van de ziekte van Alzheimer, komt er nu toch groen licht.

Alzheimer: Europese geneesmiddelenwaakhond geeft toch groen licht voor eerste behandeling

De Tijd

Belgium

Alzheimer's: European drug watchdog gives green light for first treatment after all

The European Medicines Agency (EMA) has partially approved a highly anticipated drug for the treatment of Alzheimer's disease. The latter was given permission for patients in the early stages of the disease, the EMA informed in a press release. At the same time, the agency initially did not recommend the product in July.

Evropská agentura pro léčivé přípravky (EMA) částečně schválila velmi očekávaný preparát pro léčbu Alzheimerovy choroby. Ten dostal povolení pro pacienty v raných stadiích nemoci, informovala EMA v tiskové zprávě. Agentura přitom původně přípravek v červenci nedoporučila.

Evropské úřady schválily první opravdový lék na Alzheimerovu chorobu

Česká televize

European authorities have approved the first real cure for Alzheimer's disease

This Thursday, the expert committee of the European Medicines Agency (EMA) recommended the approval of the drug lecanemab to people with Alzheimer's disease who suffer from mild cognitive impairment or mild dementia. In its recommendation, it states that this treatment can only be initiated and supervised by doctors who are experts in the diagnosis and treatment of Alzheimer's who have sufficient technology, especially MRI, for proper monitoring…

Este jueves, el comité de expertos de la Agencia Europea del Medicamento (EMA, por sus siglas en inglés) recomendó la aprobación del fármaco lecanemab a personas con enfermedad de Alzheimer que padezcan deterioro cognitivo leve o demencia leve. En su recomendación señala que este tratamiento solo puede ser iniciado y supervisado por médicos expertos en el diagnóstico y tratamiento del alzhéimer que dispongan de la tecnología suficiente, especial…

Qué es lecanemab, el primer fármaco que ralentiza el avance del alzhéimer y que acaba de aprobar la EMA

sport.es

What is lecanemab, the first drug that slows the progression of Alzheimer's disease and that has just been approved by the EMA

In Germany alone, more than a million people live with Alzheimer's. The drug Lecanemab could help some of them. The drug is now recommended for some patients.

Allein in Deutschland leben mehr als eine Million Menschen mit Alzheimer. Einigen davon könnte das Medikament Lecanemab helfen. Für manche Patienten wird das Mittel nun empfohlen.

Leqembi Okayed for Subset of Early Alzheimer’s Patients

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics